<DOC>
	<DOCNO>NCT01000480</DOCNO>
	<brief_summary>This trial investigate pemetrexed cisplatin follow pemetrexed cisplatin combination radiotherapy participant locally advance , non-small cell lung cancer ( NSCLC ) . The purpose study assess antitumor activity measure progression free survival 1 year start treatment study drug .</brief_summary>
	<brief_title>A Study Pemetrexed Cisplatin , Non Small Cell Lung Cancer</brief_title>
	<detailed_description>The participant receive 2 cycle pemetrexed cisplatin . If participant achieve complete response , partial response stable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) guideline , â‰¤35 % total calculated lung volume receive 20 Gy ( V20 ) accord 3-dimensional ( 3-D ) radiotherapy plan Dose Volume Histograms , Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 , residual neurological toxicity &gt; Grade 2 accord Common Terminology Criteria Adverse Events ( CTCAE ) , receive 2 additional cycle pemetrexed cisplatin , combine radiotherapy . The combination radiotherapy begin 22 36 day completion second infusion induction therapy pemetrexed-cisplatin .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic cytologic diagnosis unresectable nonsquamous Stage IIIA Stage IIIB ( without malignant pleural/pericardial effusion ) NSCLC . Have ECOG performance status 0 1 . Previous radiation therapy limit must include thoracic radiation , whole pelvis radiation , radiation &gt; 25 % participant 's bone marrow , participant must recover toxic effect radiation treatment prior study enrollment ( except alopecia ) . Prior radiotherapy must complete 30 day study entry . Have least 1 unidimensionally measurable lesion meeting RECIST guideline , version 1.0 . Estimated life expectancy least 12 week . Participant compliance geographic proximity allow adequate followup . Adequate bone marrow reserve , hepatic , renal pulmonary function . Participants must sign Informed Consent Document . Participants must total lung V20 le equal 35 % . For woman : Must surgically sterile , postmenopausal , compliant medically approve contraceptive regimen , 6 month treatment period ; must negative serum pregnancy test within 7 day study enrollment must breastfeed . For men : Must surgically sterile compliant contraceptive regimen 6 month treatment period . Have receive prior systemic anticancer therapy NSCLC . Have receive treatment within last 30 day enrollment drug receive regulatory approval indication time study entry . Have previously complete withdrawn study study investigate pemetrexed . Have serious concomitant systemic disorder , opinion investigator , would compromise participant 's ability adhere protocol . Have serious cardiac condition , myocardial infarction within 6 month , angina , heart disease , define New York Heart Association Class III IV . Have prior malignancy NSCLC , carcinoma situ cervix , nonmelanoma skin cancer , unless prior malignancy diagnose definitively treat least 5 year previously subsequent evidence recurrence . Participants history lowgrade ( Gleason score less equal 6 ) localize prostate cancer eligible even diagnose less 5 year previously . Are receive concurrent administration antitumor therapy . Have weight loss 10 % previous 3 month study entry . Are unable interrupt aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) , aspirin dose less equal 1.3 gram per day , least 2 day ( 5 day longacting agent ) , day , least 2 day administration pemetrexed . Are unable unwilling take folic acid vitamin B12 supplementation . Are unable unwilling take corticosteroid . Have receive recent yellow fever vaccination ( within 30 day enrollment ) receive concurrent yellow fever vaccination . Have know hypersensitivity pemetrexed , cisplatin , excipients medicinal product . Have evidence clinical hearing loss . Have clinically significant thirdspace fluid collection , control drainage procedure prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>